2026-10-12T00:14:10Z https://www.scidb.cn/oai

10.57760/sciencedb.zhjhhhxzz.00794 2026-03-04T10:36:01Z

2026-03-04 Retrospective analysis of the efficacy and safety of omadacycline in the treatment of pulmonary infections doi:10.57760/sciencedb.zhjhhhxzz.00794 en Objective To investigate the efficacy and safety of omadacycline in the treatment of pulmonary infections in a tertiary hospital.Methods A retrospective analysis was conducted on the clinical data of patients with pulmonary infections who received omadacycline treatment from January 2023 to June 2025. The efficacy and safety of the treatment were evaluated, and univariate and multivariate logistic regression analyses were performed to identify the factors associated with treatment failure of omadacycline for pulmonary infections.Results A total of 107 patients were enrolled, including 72 cases of community-acquired pneumonia. The overall clinical response rate was 80.4% (86/107), and the microbiological eradication rate was 62.5% (15/24). Targeted therapy was administered in 52 patients, among whom 24 had multidrug-resistant bacterial infections. The efficacy of monotherapy was significantly higher than that of combination therapy (58.1% vs. 41.9%, P=0.001), and there was no statistically significant difference in efficacy among different classes of combined anti-infective agents (P>0.05). Significant differences were detected in body temperature, white blood cell count, neutrophil percentage, C-reactive protein and procalcitonin between pre-treatment and post-treatment in all patients and the clinical response group (P<0.05). Hepatic injury occurred in 4 cases (5.2%), acute kidney injury (AKI) in 1 case (1.4%), decreased prothrombin time in 31 cases (64.6%), decreased D-dimer in 22 cases (59.5%), and decreased fibrinogen in 32 cases (66.7%). Multivariate logistic regression analysis demonstrated that age, APACHE II score, SOFA score, ICU admission, endotracheal intubation, continuous renal replacement therapy, targeted therapy, combination therapy and multidrug-resistant bacterial infections were risk factors for omadacycline treatment failure. In contrast, hypofibrinogenemia, on-label drug use and non-severe community-acquired pneumonia were protective factors for favorable clinical outcomes with omadacycline.Conclusion In clinical practice, omadacycline should be administered in accordance with its approved indications, and combination therapy is not recommended. Close monitoring of liver function and fibrinogen levels were warranted during treatment. Omadacycline; Pulmonary infections; Efficacy; Safety; Influencing factors Jinfang.Shi Xiaoying.Gong Dong.Qiu Yinhua.Gong Jie.Gao PUBLIC https://creativecommons.org/publicdomain/zero/1.0/ dataset Science Data Bank